GTX-102

· Ultragenyx Pharmaceutical Inc

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for GTX-102, covering 2026-01-07 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) [Phase 2]

See pricing